As payer and provider organizations look to improve health outcomes around the far-reaching impacts of the pandemic, they must consider the unique needs of some of our most vulnerable populations, such as new and expecting mothers and their infants.
Enterprise imaging platforms would enable organizations to consistently and optimally capture, index, manage, store, distribute, view, exchange and analyze all clinical imaging and multimedia content, enhancing patients’ electronic health records.
FDA approvals this week include: novel treatment for invasive candidiasis, an accelerated approval to Zynyz for Merkel cell carcinoma, the high-concentration Humira biosimilar Hyrimoz, and extension of Evkeeza’s indication to include young children. The agency also issued two complete responses this week: for Incyte’s extended-release Jakafi and for AbbVie’s Parkinson’s therapy.
Due to one of the most challenging global crises in living memory and one that presented an acute challenge for the medical community, healthcare providers find themselves operating within an uncertain landscape. They are still managing the fallout of COVID-19 while also planning for the future.
Pharmacogenomics looks at how genetic influences affect an individual’s response to therapeutic medications.
The delivery of care model needs to scale across the community settings while servicing the unique needs of each patient.
The FDA rejected Humanigen’s application for an emergency use authorization, but the race is on to develop an effective therapy for the cytokine storms that affect patients with COVID-19.
Identifying the right payer before a healthcare service is provided and billing on time, reduces costs, prevents bad debt and maximizes reimbursements and revenue.
Organizations setting up hospital-at-home programs need to be aware of the associated risks and mitigation best practices.
CMS and state officials are using payment incentives, data collection and program requirements to start edging the lofty ideals of health equity toward reality.
Engaging with payers in collaborative arrangements is critical for achieving quality outcomes at lower cost, while ensuring financial health for providers during good times and bad.
Plan sponsors should begin evaluation of PBM performance at least a year before the contract expires, say lawyers with expertise in PBM contracting.
Health plans need to consider regulations and keep healthcare data secure to take full advantage of its enormous potential to broaden and reshape timely, effective delivery of care.
Patients with chronic conditions like asthma, diabetes, and cardiovascular disease often require emergency attention and hospitalization due to non-adherence, resulting in higher treatment costs.
Research has linked many drugs to QT prolongation and decision support tools could alert clinicians to the risk and guide prescribing decisions to safer alternatives.
As industries across the board move towards a digital-only world, pharma companies must account for the different technologies that are transforming the R&D process.
Plan sponsors should begin evaluation of PBM performance at least a year before the contract expires, say lawyers with expertise in PBM contracting.
In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Hospital leaders who have historically viewed price transparency as potentially disastrous can tap into these three tips to leave that mindset behind and capitalize on the opportunities that price transparency provides.
One year into the COVID-19 pandemic and healthcare leaders are taking a hard look at all operations – especially innovative reimbursement models that best meet the needs of their business, providers and patients. No doubt these leaders are finally paying closer attention to value-based care.
The transition from treating patients at a provider’s site to delivering care in the home and community requires two things: an ability to incorporate social determinants of health into the care coordination process and the inclusion of value-based care and community-based organizations as compensated care delivery partners in VBC networks.
The pandemic has led to the adoption of telehealth and greater access to care through apps.
Types of patients who will likely benefit from long-acting injectable PrEP therapies in the HIV treatment pipeline.
Does your transition to Alternate Payment Model Performance Pathways (APP) quality reporting have your ACO scrambling for data? No surprise.
This opinion piece contributed by Draper voices today's digital platforms can help eliminate the administrative burden on nurses.
As the clinician shortage continues, leaning on technology to streamline inefficiencies is essential.
Optimizing your Star Rating program with machine learning technology.